Related Experiment Video
Updated: Nov 13, 2025
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Clinical oncology research; Review on contemporary methodology standards
Mohamed Mahmood Nasr1, Maged Mahmoud Nasr2, Lamia Hamed Shehata3
1King Fahd Hospital, Ministry of Health, Riyadh, Kingdom of Saudi Arabia.
Abstract:
Evaluation of novel treatments through clinical trials remains the backbone of oncological clinical research, but only a minor portion have been tested in Phase III trials. The continued publication of underpowered trials provides an ongoing need for meta-analyses to detect clinically significant outcomes. Although tumor relapse and survival are important issues and easily measured outcomes in trials, they are often not the most relevant indicators for treatment success. As diagnostic technologies and treatments continue to advance, methodologies defining high quality studies have been established, but still enthusiasm to adopt novel technologies that leads to studies holding well-described bias that do not aid the rational use of the studied test. Global awareness of such bias and standard research methodology is the clue toward iconic studies giving rational supporting novel cancer treatments and patients' support.
Insights
Clinical trials are crucial for cancer research, but many are underpowered. Meta-analyses are needed to interpret results, especially when novel diagnostic technologies introduce bias, impacting treatment decisions.
Area of Science:
- Oncology
- Clinical Research Methodology
Background:
- Clinical trials are essential for evaluating new cancer treatments, but few reach Phase III.
- Underpowered studies are frequently published, necessitating meta-analyses for outcome detection.
- Traditional outcomes like survival may not fully represent treatment success with advancing diagnostics.
Purpose of the Study:
- To highlight the need for robust methodologies in oncological clinical trials.
- To address the challenges posed by underpowered studies and publication bias.
- To emphasize the importance of evaluating novel diagnostic technologies and their impact on research quality.
Main Methods:
- Review of current practices in oncological clinical trial design and analysis.
- Discussion of the role and limitations of meta-analyses in interpreting trial data.
- Analysis of bias introduced by novel diagnostic technologies in cancer research.
Main Results:
- A significant portion of published trials lack sufficient power.
- Meta-analyses are critical for synthesizing evidence from underpowered studies.
- Bias in studies evaluating new technologies can hinder rational treatment adoption.
Conclusions:
- Standardized research methodology and awareness of bias are crucial for reliable cancer treatment evaluation.
- High-quality studies are needed to support the rational use of novel cancer therapies.
- Improved trial design and critical appraisal are essential for advancing patient care in oncology.
Related Concept Videos
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Standards of Care II
01:22Standards of Care I